CD274 and cancer: Food and Drug Administration (FDA) has approved serval monoclonal antibodies (mAb) targeting PD‐L1/PD1 signaling for cancer therapy, including three PD‐L1 mAb (atezolizumab or Tecentriq, durvalumab or Imfinzi, and avelumab or Bavencio) and three PD‐1 mAb (pembrolizumab or Keytruda, nivolumab or Opdivo, and cemiplimab or Libtayo).